Keryx Biopharmaceuticals (KERX) Said SUN-MICRO Trial Failed to Meet its Primary Efficacy Endpoint
Tweet Send to a FriendGet Alerts KERX Hot Sheet
Up)
Trade KERX Now!
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced top-line results from its SUN-MICRO Phase 3 clinical trial of Sulonex for the treatment of diabetic nephropathy. The Company announced that this Phase 3 clinical trial failed to meet the primary objective of the study, which was to increase the proportion of patients that achieve therapeutic success at 6 months as compared to placebo over background therapy of maximal doses of ACE-inhibitors or ARBs.
You May Also Be Interested In
- Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
- Agilent (A) Tops Q2 EPS by 9c, Trims FY13 Outlook; Adds to Buyback, Will Cut Jobs
- Santarus (SNTS) to Present Additional Data on UCERIS
Create E-mail Alert Related Categories
FDA, Hot List
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
